Dimensional Fund Advisors LP Invests $296,000 in Proteostasis Therapeutics Inc (PTI) Stock

Dimensional Fund Advisors LP acquired a new stake in shares of Proteostasis Therapeutics Inc (NASDAQ:PTI) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 63,153 shares of the company’s stock, valued at approximately $296,000. Dimensional Fund Advisors LP owned approximately 0.25% of Proteostasis Therapeutics as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the stock. Bank of New York Mellon Corp increased its holdings in shares of Proteostasis Therapeutics by 17.3% in the 1st quarter. Bank of New York Mellon Corp now owns 34,964 shares of the company’s stock worth $273,000 after purchasing an additional 5,153 shares in the last quarter. LMR Partners LLP bought a new stake in shares of Proteostasis Therapeutics in the 2nd quarter worth $127,000. FMR LLC increased its holdings in shares of Proteostasis Therapeutics by 2.3% in the 2nd quarter. FMR LLC now owns 2,944,915 shares of the company’s stock worth $13,782,000 after purchasing an additional 66,111 shares in the last quarter. Finally, Jennison Associates LLC increased its holdings in shares of Proteostasis Therapeutics by 6.2% in the 2nd quarter. Jennison Associates LLC now owns 2,075,439 shares of the company’s stock worth $9,713,000 after purchasing an additional 120,575 shares in the last quarter. 68.08% of the stock is owned by institutional investors.

PTI has been the subject of a number of research analyst reports. Leerink Swann reissued an “outperform” rating and issued a $9.00 target price (down previously from $17.00) on shares of Proteostasis Therapeutics in a report on Wednesday, August 16th. Zacks Investment Research lowered Proteostasis Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 18th.

Proteostasis Therapeutics Inc (PTI) opened at $2.48 on Thursday. Proteostasis Therapeutics Inc has a 52 week low of $1.41 and a 52 week high of $16.67.

Proteostasis Therapeutics (NASDAQ:PTI) last released its quarterly earnings results on Tuesday, November 14th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.72) by $0.16. The firm had revenue of $1.55 million for the quarter, compared to the consensus estimate of $1.38 million. Proteostasis Therapeutics had a negative return on equity of 93.15% and a negative net margin of 712.49%. sell-side analysts anticipate that Proteostasis Therapeutics Inc will post -2.47 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://www.thelincolnianonline.com/2017/12/07/dimensional-fund-advisors-lp-invests-296000-in-proteostasis-therapeutics-inc-pti-stock.html.

Proteostasis Therapeutics Profile

Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.

Institutional Ownership by Quarter for Proteostasis Therapeutics (NASDAQ:PTI)

Receive News & Ratings for Proteostasis Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply